Developer docs
API playgroundTry for free, no card

Search company profiles

o2h Discovery

Full company profile

uuid006749q

Namestring
o2h Discovery
Legal namestring
o2h Discovery Private Limited
Websiteurl
o2hdiscovery.co
Company typeenum
Private
Founded yearint
2005
Descriptiontext

o2h Discovery is a privately held, integrated drug discovery contract research organization (CRO) founded in 2005 and headquartered in Cambridge, UK, with a large research centre in Ahmedabad, India and a North American field office in Cambridge, MA. The company runs a multi-modality platform spanning medicinal and synthetic chemistry, peptide synthesis, PROTAC and lipid nanoparticle (LNP) chemistry, biology (assay development, FRET/BRET, fragment-based screening with Biacore T200 SPR, CRISPR/Cas9, NanoBRET), DMPK (including the ChamelogK chameleonicity assay for PROTACs), and kilo-lab to non-GMP scale-up (with GMP via partnership). Its dedicated capabilities are anchored by proprietary assets including CITC (Chemistry in the Cloud), an award-winning cloud-based project management and ELN app, the trademarked o2h Peptide Guarantee programme with a 2-week delivery SLA, and a curated ~600-fragment FBDD library.

The firm serves three primary segments: large pharmaceutical companies (with marquee engagements scaled up to 52 FTEs over a decade-plus horizon), mid-to-large biotechnology firms (especially in PROTAC, LNP, and IND-enabling workflows), and seed-to-Series-B early-stage biotechs that are funnelled through the o2h Kickstarter subsidised-services programme (now spanning Global, Japan, North America, and Peptide editions) and supplementary programmes like o2h Biology Match Funding, o2h Plug-in Biotech, and InflexionTx co-discovery match-funding. Customer evidence points to ~200 global partners across 35+ countries, with publicly named relationships including Karyopharm, NeoPhore, Protai, Refoxy Pharma, QEDDI/UniQuest, RVAC Medicines, Cellestial Health, and Sentinel Oncology.

Commercially, o2h operates a primarily fee-for-service model — billable FTE hours, per-project fees, and milestone payments for integrated drug discovery — supplemented by a community-led growth motion (Kickstarter awards, OBN and PIA UK awards presence, the Cambridge Wide Open Week, and an annual o2h Innovation Conference). The company is bootstrapped and privately held by co-founders Prashant Shah (CEO) and Sunil Shah, with no disclosed external institutional investors or parent holding company identified in the source material. Recent strategic emphasis has shifted toward AI-augmented target identification (OutSee partnership), geographic expansion of the startup funnel (Japan and North America editions), and SLA-backed peptide chemistry as a differentiated product line.

Short descriptiontext

o2h Discovery is a privately held, integrated drug-discovery CRO founded in 2005, headquartered in Cambridge, UK, with a large Ahmedabad, India research centre and a Cambridge, MA field office. It delivers medicinal chemistry, biology, DMPK, scale-up, PROTAC, LNP, FBDD, and peptide-synthesis services via billable FTE and project-based pricing to pharma, biotech, and early-stage startup customers across ~35 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, contract research organization, medicinal chemistry, biology assays, preclinical development
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery CRO Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

Fee-for-service CRO model providing integrated drug discovery services including chemistry, biology, DMPK, and scale-up on a project-by-project basis. Revenue generated through billable FTE (full-time equivalent) hours, per-project fees, and milestone-based payments.

o2hdiscovery.co
2Kickstarter Awards Program
TypeAffiliate Referral
Description

Provides subsidized or free discovery services to early-stage biotech startups in exchange for case studies, testimonials, and potential long-term commercial partnerships. Creates pipeline for future paid engagements.

o2hdiscovery.co
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Custom project-based pricing for integrated drug discovery services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies by project scope including chemistry, biology, DMPK, and scale-up services. Quote-based engagement model typical for CRO services.

o2hdiscovery.co
2o2h Kickstarter Peptide Award - subsidized discovery support for early-stage biotech
ModelOtherBilling cadenceMulti-year contract
Notes

Provides 100 peptides synthesis, 100 ADME data points, and FTE access at reduced cost for peptide-focused startups. Stage 1 includes 25 ADME points, Stage 2 adds 75 additional ADME points and 6-month FTE support.

o2hdiscovery.co
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

o2h Discovery is an integrated contract research organization (CRO) providing end-to-end small-molecule drug discovery services for biotech and pharmaceutical companies. Its core offerings span medicinal and synthetic chemistry, peptide synthesis (with a 2-week delivery guarantee), PROTAC synthesis, lipid nanoparticles, ADCs, biology (target engagement, assay development, drug screening), DMPK studies, and scale-up synthesis (kilo-lab to GMP), delivered from Cambridge UK and Ahmedabad India by a team of 750+ scientists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 2-week guaranteed peptide delivery for standard linear peptides up to 20 amino acids
+3 more records
Product overview1 text field

o2h Discovery operates a multi-modality integrated drug discovery platform combining chemistry, biology, DMPK, and scale-up services. The core offering spans integrated drug discovery (target ID to pre-clinical candidate), supplemented by specialized chemistry services (medicinal/synthetic chemistry, peptide synthesis, PROTACs, LNPs, ADCs), biology services (target engagement, assay biology, drug screening, gene expression), and DMPK services (in-vitro/in-vivo PK). Key differentiated offerings include the 2-week o2h Peptide Guarantee for fast peptide delivery, CITC (Chemistry in the Cloud) proprietary project management app, and the o2h Kickstarter Award program providing FTE support to early-stage biotechs. The platform also includes specialized capabilities in FRET/BRET assays, Fragment-Based Drug Discovery (FBDD), and strategic partnerships like the OutSee collaboration for AI-driven genomics. Services are delivered from research centers in Cambridge, UK and Ahmedabad, India with over 750 scientists.

Product and service1 record
1Integrated Drug Discovery
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

Strategic collaboration with OutSee for joint drug discovery program focused on OutSee's lead AI-identified target candidate. o2h discovery provides chemistry services and funding through its InflexionRx partnership program to build a library of drug candidates for OutSee's Nomaly platform.

2Genomics England
Strategic tierMinorTypeStrategic or Co-development Partner
Description

OutSee partner mentioned in context of genomics platform applications

o2hdiscovery.co
Strategic tierMinorTypeStrategic or Co-development Partner
Description

OutSee partner mentioned for genomic data collaboration

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

o2h Discovery listed on Scientist.com marketplace for biotech research procurement

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large, publicly-traded integrated drug discovery CRO offering multi-modality platform and discovery partnerships across therapeutic areas; competes with o2h for larger pharma integrated discovery outsourcing deals.

TypeBroad incumbent
Description

Largest global CRO/CDMO with extensive preclinical discovery, biology, and DMPK operations; competes on integrated deals for both small-molecule and biologics discovery.

TypeDirect peer
Description

UK-based preclinical CRO with integrated chemistry and biology capabilities serving similar biotech and pharma early-discovery needs as o2h.

TypeDirect peer
Description

China-headquartered CRO with strong UK/US presence offering integrated chemistry, biology, DMPK, and scale-up services closely comparable to o2h's integrated model.

TypeBroad incumbent
Description

Global CRO incumbent spanning discovery and safety assessment; competes with o2h for biotech and pharma preclinical contracts, though with a significantly broader service portfolio.

TypeBroad incumbent
Description

International CRO offering medicinal chemistry, biology, and pharmacology services as part of a broader life-sciences testing portfolio; comparable buyer-side overlap in discovery outsourcing.

7Jubilant Biosys
TypeDirect peer
Description

India-based preclinical CRO with integrated discovery chemistry and biology offerings; peer in the integrated India/global discovery services category.

TypeDirect peer
Description

UK-headquartered preclinical CRO offering integrated medicinal chemistry, biology, and DMPK services of similar size and customer mix to o2h Discovery, targeting biotech and pharma discovery programs.

TypeDirect peer
Description

India-headquartered CRO offering integrated discovery chemistry and biology services similar in scope and operating philosophy to o2h's India platform, serving biotech and pharma globally.

TypeDirect peer
Description

European CRO with comparable scale offering integrated medicinal chemistry, biology, and DMPK discovery services to biotech and pharma clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

o2h Discovery

Drug Discovery CRO Serviceso2hdiscovery.co

o2h Discovery is a privately held, integrated drug-discovery CRO founded in 2005, headquartered in Cambridge, UK, with a large Ahmedabad, India research centre and a Cambridge, MA field office. It delivers medicinal chemistry, biology, DMPK, scale-up, PROTAC, LNP, FBDD, and peptide-synthesis services via billable FTE and project-based pricing to pharma, biotech, and early-stage startup customers across ~35 countries.

What o2h Discovery does

o2h Discovery is a privately held, integrated drug discovery contract research organization (CRO) founded in 2005 and headquartered in Cambridge, UK, with a large research centre in Ahmedabad, India and a North American field office in Cambridge, MA. The company runs a multi-modality platform spanning medicinal and synthetic chemistry, peptide synthesis, PROTAC and lipid nanoparticle (LNP) chemistry, biology (assay development, FRET/BRET, fragment-based screening with Biacore T200 SPR, CRISPR/Cas9, NanoBRET), DMPK (including the ChamelogK chameleonicity assay for PROTACs), and kilo-lab to non-GMP scale-up (with GMP via partnership). Its dedicated capabilities are anchored by proprietary assets including CITC (Chemistry in the Cloud), an award-winning cloud-based project management and ELN app, the trademarked o2h Peptide Guarantee programme with a 2-week delivery SLA, and a curated ~600-fragment FBDD library.

The firm serves three primary segments: large pharmaceutical companies (with marquee engagements scaled up to 52 FTEs over a decade-plus horizon), mid-to-large biotechnology firms (especially in PROTAC, LNP, and IND-enabling workflows), and seed-to-Series-B early-stage biotechs that are funnelled through the o2h Kickstarter subsidised-services programme (now spanning Global, Japan, North America, and Peptide editions) and supplementary programmes like o2h Biology Match Funding, o2h Plug-in Biotech, and InflexionTx co-discovery match-funding. Customer evidence points to ~200 global partners across 35+ countries, with publicly named relationships including Karyopharm, NeoPhore, Protai, Refoxy Pharma, QEDDI/UniQuest, RVAC Medicines, Cellestial Health, and Sentinel Oncology.

Commercially, o2h operates a primarily fee-for-service model — billable FTE hours, per-project fees, and milestone payments for integrated drug discovery — supplemented by a community-led growth motion (Kickstarter awards, OBN and PIA UK awards presence, the Cambridge Wide Open Week, and an annual o2h Innovation Conference). The company is bootstrapped and privately held by co-founders Prashant Shah (CEO) and Sunil Shah, with no disclosed external institutional investors or parent holding company identified in the source material. Recent strategic emphasis has shifted toward AI-augmented target identification (OutSee partnership), geographic expansion of the startup funnel (Japan and North America editions), and SLA-backed peptide chemistry as a differentiated product line.

o2h Discovery firmographics

Firmographics
Name
o2h Discovery
Legal name
o2h Discovery Private Limited
Website
https://o2hdiscovery.co
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
501–1,000 employees
Short description
o2h Discovery is a privately held, integrated drug-discovery CRO founded in 2005, headquartered in Cambridge, UK, with a large Ahmedabad, India research centre and a Cambridge, MA field office. It delivers medicinal chemistry, biology, DMPK, scale-up, PROTAC, LNP, FBDD, and peptide-synthesis services via billable FTE and project-based pricing to pharma, biotech, and early-stage startup customers across ~35 countries.
Ownership category
akta.pro rank

o2h Discovery industry classification

Industry
Product category
Drug Discovery CRO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Drug discovery services
  • Contract research organization
  • Medicinal chemistry
  • Biology assays
  • Preclinical development

Where o2h Discovery is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

o2h Discovery business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Services: Fee-for-service CRO model providing integrated drug discovery services including chemistry, biology, DMPK, and scale-up on a project-by-project basis. Revenue generated through billable FTE (full-time equivalent) hours, per-project fees, and milestone-based payments.
  2. Kickstarter Awards Program: Provides subsidized or free discovery services to early-stage biotech startups in exchange for case studies, testimonials, and potential long-term commercial partnerships. Creates pipeline for future paid engagements.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for integrated drug discovery services
OtherMulti-year contracto2h Kickstarter Peptide Award - subsidized discovery support for early-stage biotech

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

o2h Discovery product offering

Product offering

Core offering

o2h Discovery is an integrated contract research organization (CRO) providing end-to-end small-molecule drug discovery services for biotech and pharmaceutical companies. Its core offerings span medicinal and synthetic chemistry, peptide synthesis (with a 2-week delivery guarantee), PROTAC synthesis, lipid nanoparticles, ADCs, biology (target engagement, assay development, drug screening), DMPK studies, and scale-up synthesis (kilo-lab to GMP), delivered from Cambridge UK and Ahmedabad India by a team of 750+ scientists.

Product overview

o2h Discovery operates a multi-modality integrated drug discovery platform combining chemistry, biology, DMPK, and scale-up services. The core offering spans integrated drug discovery (target ID to pre-clinical candidate), supplemented by specialized chemistry services (medicinal/synthetic chemistry, peptide synthesis, PROTACs, LNPs, ADCs), biology services (target engagement, assay biology, drug screening, gene expression), and DMPK services (in-vitro/in-vivo PK). Key differentiated offerings include the 2-week o2h Peptide Guarantee for fast peptide delivery, CITC (Chemistry in the Cloud) proprietary project management app, and the o2h Kickstarter Award program providing FTE support to early-stage biotechs. The platform also includes specialized capabilities in FRET/BRET assays, Fragment-Based Drug Discovery (FBDD), and strategic partnerships like the OutSee collaboration for AI-driven genomics. Services are delivered from research centers in Cambridge, UK and Ahmedabad, India with over 750 scientists.

Differentiator

Problem solved

Functional benefit

Products and services

  • Integrated Drug Discovery

Quantifiable outcome

  • 2-week guaranteed peptide delivery for standard linear peptides up to 20 amino acids
  • +3 more outcomes

Companies that use o2h Discovery

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

o2h Discovery technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

o2h Discovery partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • OutSeecoreStrategic or Co-development Partner · 22 January 2026Strategic collaboration with OutSee for joint drug discovery program focused on OutSee's lead AI-identified target candidate. o2h discovery provides chemistry services and funding through its InflexionRx partnership program to build a library of drug candidates for OutSee's Nomaly platform.
  • Genomics EnglandminorStrategic or Co-development PartnerOutSee partner mentioned in context of genomics platform applications
  • FinnGenminorStrategic or Co-development PartnerOutSee partner mentioned for genomic data collaboration
  • Scientist.comminorChannel Partner/ Reseller/ Distributoro2h Discovery listed on Scientist.com marketplace for biotech research procurement

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

o2h Discovery competitors and assessment

Company assessment

Broad incumbents

  • Evotec SE: Large, publicly-traded integrated drug discovery CRO offering multi-modality platform and discovery partnerships across therapeutic areas; competes with o2h for larger pharma integrated discovery outsourcing deals.
  • WuXi AppTec: Largest global CRO/CDMO with extensive preclinical discovery, biology, and DMPK operations; competes on integrated deals for both small-molecule and biologics discovery.
  • Charles River Laboratories: Global CRO incumbent spanning discovery and safety assessment; competes with o2h for biotech and pharma preclinical contracts, though with a significantly broader service portfolio.
  • Eurofins Discovery: International CRO offering medicinal chemistry, biology, and pharmacology services as part of a broader life-sciences testing portfolio; comparable buyer-side overlap in discovery outsourcing.

Direct peers

  • Concept Life Sciences: UK-based preclinical CRO with integrated chemistry and biology capabilities serving similar biotech and pharma early-discovery needs as o2h.
  • Pharmaron: China-headquartered CRO with strong UK/US presence offering integrated chemistry, biology, DMPK, and scale-up services closely comparable to o2h's integrated model.
  • Jubilant Biosys: India-based preclinical CRO with integrated discovery chemistry and biology offerings; peer in the integrated India/global discovery services category.
  • Sygnature Discovery: UK-headquartered preclinical CRO offering integrated medicinal chemistry, biology, and DMPK services of similar size and customer mix to o2h Discovery, targeting biotech and pharma discovery programs.
  • Aragen Life Sciences (formerly GVK Bio): India-headquartered CRO offering integrated discovery chemistry and biology services similar in scope and operating philosophy to o2h's India platform, serving biotech and pharma globally.
  • Selvita: European CRO with comparable scale offering integrated medicinal chemistry, biology, and DMPK discovery services to biotech and pharma clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

o2h Discovery social profiles

Digital presence

o2h Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

o2h Discovery leadership team

Management profile

Number of profiles

Profiles6 records

o2h Discovery funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

o2h Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about o2h Discovery

What does o2h Discovery do?

o2h Discovery is an integrated contract research organization (CRO) providing end-to-end small-molecule drug discovery services for biotech and pharmaceutical companies. Its core offerings span medicinal and synthetic chemistry, peptide synthesis (with a 2-week delivery guarantee), PROTAC synthesis, lipid nanoparticles, ADCs, biology (target engagement, assay development, drug screening), DMPK studies, and scale-up synthesis (kilo-lab to GMP), delivered from Cambridge UK and Ahmedabad India by a team of 750+ scientists.

Is o2h Discovery a public or private company?

o2h Discovery is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was o2h Discovery founded?

o2h Discovery was founded in 2005. It employs 501 to 1,000 people.

Where is o2h Discovery based?

o2h Discovery is headquartered in Cambridge, United Kingdom, in the Europe region.

How does o2h Discovery make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are kickstarter Awards Program.

Who are o2h Discovery's main competitors?

Broad incumbents on record are Evotec SE, WuXi AppTec, Charles River Laboratories and Eurofins Discovery. Direct peers are Concept Life Sciences, Pharmaron, Jubilant Biosys, Sygnature Discovery, Aragen Life Sciences (formerly GVK Bio) and Selvita.

Does o2h Discovery have an API?

No public API is recorded for o2h Discovery.

What industry is o2h Discovery in?

o2h Discovery's product category is Drug Discovery CRO Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AI InsiderOutSee Raises £2.5M Seed and Partners With o2h Discovery to Advance AI-Driven Drug Target DevelopmentOutSee, a genomics and drug discovery company, has closed a £2.5 million seed funding round and signed a strategic collaboration with preclinical CRO o2h discovery to advance a joint drug discovery programme focused on OutSee's lead AI-identified target candidate. The seed round was led by Ahren Innovation Capital with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 angel investors, completing a first close announced in June 2025. The funding will support experimental validation of multiple AI-identified targets and continued development of OutSee's Nomaly precision medicine platform.News-MedicalOutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidateOutSee, a genomics and drug discovery company, has closed a £2.5 million seed funding round led by Ahren Innovation Capital with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 angel investors. The company has simultaneously established a strategic partnership with o2h discovery, a preclinical contract research organization, to launch a collaborative drug discovery program for OutSee's lead target candidate using its AI-powered Nomaly platform. The partnership is supported by o2h's co-discovery InflexionRx match funding model covering proof-of-concept studies at the HIT ID Phase.Pulse 2.0OutSee: £2.5 Million Seed Round Completed And Partnership With o2h DiscoveryOutSee, an AI-enabled genomics and drug discovery company, has closed a £2.5 million oversubscribed seed funding round led by Ahren Innovation Capital, with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 angel investors. The company simultaneously signed a strategic partnership with o2h discovery to launch its first collaborative drug discovery programme, combining OutSee's precision medicine platform Nomaly with o2h's integrated preclinical discovery platform. The funding will support experimental validation of targets generated by Nomaly and the buildout of an internal asset pipeline.Business Wire BlogOutSee Completes Seed Funding Round and Establishes Partnership With o2h Discovery for Lead Drug Target CandidateOutSee, a Cambridge-based genomics and drug discovery company, has completed an oversubscribed £2.5M seed funding round led by Ahren Innovation Capital, with participation from Kadmos Capital, Panacea, Empirical Ventures, and 26 independent angel investors. The company also signed a strategic partnership with o2h Discovery, a preclinical contract research organisation, to launch a collaborative drug discovery programme for OutSee's lead target candidate using o2h's co-discovery InflexionTx model. The funding will support advancement of therapeutic targets through experimental validation and ongoing R&D of OutSee's Nomaly AI-powered genomics platform.MassbioThe o2h Kickstarter Award: Empowering the Future of Biotech Innovationo2h Discovery is promoting its Kickstarter Award program, which provides early-stage biotech companies with chemistry and biology support to generate critical experimental data. The article highlights success stories from partners including Serenatis Bio, Breakloop Bio, Type6 Therapeutics, Cellestial Health, and InnoVira Therapeutics, demonstrating how the program helps these firms validate hypotheses and secure further funding.MassbioFast Custom Peptide Synthesis Services for Drug Discovery: Why It Matters and How the o2h Peptide Guarantee Deliverso2h Discovery has launched a Peptide Guarantee Programme offering custom linear peptide synthesis (≥95% purity, ≤20 amino acids) with a 2-week delivery guarantee, complete with HPLC, MS, and Certificate of Analysis, versus the industry standard of 3–5 weeks. The programme targets biotech companies, academic researchers, and pharmaceutical firms requiring rapid peptide delivery for structure–activity relationship studies, bioconjugation experiments, and screening campaigns. The Cambridge, UK and Ahmedabad, India-based CRO positions this initiative as a competitive offering in the custom peptide synthesis market, with the guarantee that delayed deliveries are the company's responsibility.O2HPsylo, a biotech company developing next-gen drugs for psychiatric disorders wins o2h kickstarter competition 2.0Psylo, a Sydney-based biotech company, was selected as a winner of the o2h discovery kickstarter competition 2.0 to receive six full-time equivalent chemists for its psychedelic-inspired drug research program. This support aims to accelerate Psylo's capacity to develop novel small molecule treatments targeting the 5-HT2A receptor for neuropsychiatric conditions. The announcement follows Psylo's recent $5 million fundraising round led by several venture capital firms.